Australian Precision Medicine Enterprise (APME)

We’re growing a world-class precision medicine industry and securing Australia’s supply of advanced radiopharmaceuticals for diagnosis, therapy, and theranostics. Theranostics is precision medicine at the molecular level, combining imaging diagnostics with therapeutic drugs to detect and treat cancer and other diseases. To meet domestic and global demand, the Australian Precision Medicine Enterprise (APME) combines theranostics R&D, clinical trials and manufacturing in one world-class facility. Our state-of-the-art 30MeV & 18MeV cyclotrons and GMP-compliant radiochemistry facilities and services will be accessible to students, scientists, clinical researchers and pharmaceutical companies from Australia and around the world. We’re working with government, research and industry to: - Advance diagnoses and treatments for cancer and other diseases - Attract and train scientists and engineers for the Australian workforce - Build a globally competitive Australian manufacturing hub - Secure Australia’s supply of critical radiopharmaceuticals APME is a collaboration between Global Medical Solutions Australia, Monash University and Telix Pharmaceuticals. APME will be located at Monash University’s Innovation Precinct in Melbourne, Australia, and operated by Global Medical Solutions Australia.